Ayala Pharmaceuticals Inc. [NASDAQ: AYLA] jumped around 0.82 points on Tuesday, while shares priced at $1.69 at the close of the session, up 94.25%. The company report on July 5, 2022 that Ayala Pharmaceuticals Announces Interim Data from Part A of the Phase 2/3 RINGSIDE Trial of AL102 in Desmoid Tumors.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
– Tumor shrinking observed in substantially all patients who were evaluable at 16 weeks -.
– Favorable safety results observed: AL102 was well tolerated -.
Ayala Pharmaceuticals Inc. stock is now -80.14% down from its year-to-date (YTD) trading value. AYLA Stock saw the intraday high of $2.42 and lowest of $1.50 per share. The company’s 52-week high price is 14.95, which means current price is +141.43% above from all time high which was touched on 01/03/22.
Compared to the average trading volume of 90.22K shares, AYLA reached a trading volume of 101613568 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Ayala Pharmaceuticals Inc. [AYLA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AYLA shares is $13.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AYLA stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Ayala Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 20, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on December 20, 2021, representing the official price target for Ayala Pharmaceuticals Inc. stock. Previously, the target price had yet another raise from $12 to $17, while Jefferies kept a Buy rating on AYLA stock.
The Average True Range (ATR) for Ayala Pharmaceuticals Inc. is set at 0.23, with the Price to Sales ratio for AYLA stock in the period of the last 12 months amounting to 8.99. The Price to Book ratio for the last quarter was 1.04, with the Price to Cash per share for the same quarter was set at 1.70.
How has AYLA stock performed recently?
Ayala Pharmaceuticals Inc. [AYLA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 79.96. With this latest performance, AYLA shares gained by 57.94% in over the last four-week period, additionally sinking by -72.65% over the last 6 months – not to mention a drop of -84.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AYLA stock in for the last two-week period is set at 64.20, with the RSI for the last a single of trading hit 72.58, and the three-weeks RSI is set at 57.05 for Ayala Pharmaceuticals Inc. [AYLA]. The present Moving Average for the last 50 days of trading for this stock 1.4337, while it was recorded at 1.0398 for the last single week of trading, and 5.3080 for the last 200 days.
Ayala Pharmaceuticals Inc. [AYLA]: Deeper insight into the fundamentals
Ayala Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.50 and a Current Ratio set at 5.50.
Insider trade positions for Ayala Pharmaceuticals Inc. [AYLA]
There are presently around $4 million, or 54.90% of AYLA stock, in the hands of institutional investors. The top three institutional holders of AYLA stocks are: HAREL INSURANCE INVESTMENTS & FINANCIAL SERVICES LTD. with ownership of 2,153,273, which is approximately -0.027% of the company’s market cap and around 2.80% of the total institutional ownership; IKARIAN CAPITAL, LLC, holding 708,383 shares of the stock with an approximate value of $0.62 million in AYLA stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $0.56 million in AYLA stock with ownership of nearly -8.671% of the company’s market capitalization.
7 institutional holders increased their position in Ayala Pharmaceuticals Inc. [NASDAQ:AYLA] by around 158,040 shares. Additionally, 6 investors decreased positions by around 327,332 shares, while 3 investors held positions by with 4,298,522 shares. The mentioned changes placed institutional holdings at 4,783,894 shares, according to the latest SEC report filing. AYLA stock had 2 new institutional investments in for a total of 83,113 shares, while 1 institutional investors sold positions of 1,940 shares during the same period.